353 related articles for article (PubMed ID: 12006382)
21. Peroxisome proliferator-activated receptors (PPARS): regulators of gene expression in heart and skeletal muscle.
Gilde AJ; Van Bilsen M
Acta Physiol Scand; 2003 Aug; 178(4):425-34. PubMed ID: 12864748
[TBL] [Abstract][Full Text] [Related]
22. Differential effects of peroxisome proliferator-activated receptor activators on the mRNA levels of genes involved in lipid metabolism in primary human monocyte-derived macrophages.
Cabrero A; Cubero M; Llaverías G; Jové M; Planavila A; Alegret M; Sánchez R; Laguna JC; Carrera MV
Metabolism; 2003 May; 52(5):652-7. PubMed ID: 12759900
[TBL] [Abstract][Full Text] [Related]
23. Peroxisome proliferator-activated receptors and the regulation of mammalian lipid metabolism.
Smith SA
Biochem Soc Trans; 2002 Nov; 30(Pt 6):1086-90. PubMed ID: 12440979
[TBL] [Abstract][Full Text] [Related]
24. Peroxisome proliferator-activated receptors: new targets for the pharmacological modulation of macrophage gene expression and function.
Chinetti G; Fruchart JC; Staels B
Curr Opin Lipidol; 2003 Oct; 14(5):459-68. PubMed ID: 14501584
[TBL] [Abstract][Full Text] [Related]
25. PPAR- and LXR-dependent pathways controlling lipid metabolism and the development of atherosclerosis.
Li AC; Glass CK
J Lipid Res; 2004 Dec; 45(12):2161-73. PubMed ID: 15489539
[TBL] [Abstract][Full Text] [Related]
26. Peroxisome proliferator-activated receptor (PPAR) alpha and PPARbeta/delta, but not PPARgamma, modulate the expression of genes involved in cardiac lipid metabolism.
Gilde AJ; van der Lee KA; Willemsen PH; Chinetti G; van der Leij FR; van der Vusse GJ; Staels B; van Bilsen M
Circ Res; 2003 Mar; 92(5):518-24. PubMed ID: 12600885
[TBL] [Abstract][Full Text] [Related]
27. Peroxisome proliferator-activated receptors in atherosclerosis and inflammation--an update.
Elangbam CS; Tyler RD; Lightfoot RM
Toxicol Pathol; 2001; 29(2):224-31. PubMed ID: 11421489
[TBL] [Abstract][Full Text] [Related]
28. The role of PPARs in atherosclerosis.
Duval C; Chinetti G; Trottein F; Fruchart JC; Staels B
Trends Mol Med; 2002 Sep; 8(9):422-30. PubMed ID: 12223313
[TBL] [Abstract][Full Text] [Related]
29. PPARalpha and PPARgamma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene.
Schoonjans K; Peinado-Onsurbe J; Lefebvre AM; Heyman RA; Briggs M; Deeb S; Staels B; Auwerx J
EMBO J; 1996 Oct; 15(19):5336-48. PubMed ID: 8895578
[TBL] [Abstract][Full Text] [Related]
30. Role of the peroxisome proliferator-activated receptors (PPAR) in atherosclerosis.
Neve BP; Fruchart JC; Staels B
Biochem Pharmacol; 2000 Oct; 60(8):1245-50. PubMed ID: 11007963
[TBL] [Abstract][Full Text] [Related]
31. Peroxisome proliferator-activated receptors (PPARs) and their role in the vessel wall: possible mediators of cardiovascular risk?
Marx N; Libby P; Plutzky J
J Cardiovasc Risk; 2001 Aug; 8(4):203-10. PubMed ID: 11550998
[TBL] [Abstract][Full Text] [Related]
32. Peroxisome proliferator-activated receptor alpha in metabolic disease, inflammation, atherosclerosis and aging.
Pineda Torra I; Gervois P; Staels B
Curr Opin Lipidol; 1999 Apr; 10(2):151-9. PubMed ID: 10327283
[TBL] [Abstract][Full Text] [Related]
33. Peroxisome proliferator activated receptors and obesity.
Kersten S
Eur J Pharmacol; 2002 Apr; 440(2-3):223-34. PubMed ID: 12007538
[TBL] [Abstract][Full Text] [Related]
34. PPARgamma but not PPARalpha ligands are potent repressors of major histocompatibility complex class II induction in atheroma-associated cells.
Kwak BR; Myit S; Mulhaupt F; Veillard N; Rufer N; Roosnek E; Mach F
Circ Res; 2002 Feb; 90(3):356-62. PubMed ID: 11861426
[TBL] [Abstract][Full Text] [Related]
35. Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications.
Touyz RM; Schiffrin EL
Vascul Pharmacol; 2006 Jul; 45(1):19-28. PubMed ID: 16782410
[TBL] [Abstract][Full Text] [Related]
36. Minireview: lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors.
Lee CH; Olson P; Evans RM
Endocrinology; 2003 Jun; 144(6):2201-7. PubMed ID: 12746275
[TBL] [Abstract][Full Text] [Related]
37. Peroxisome proliferator-activated receptor alpha (PPARalpha) and athero-sclerosis.
Gouni-Berthold I; Krone W
Curr Drug Targets Cardiovasc Haematol Disord; 2005 Dec; 5(6):513-23. PubMed ID: 16503871
[TBL] [Abstract][Full Text] [Related]
38. Drug Insight: mechanisms of action and therapeutic applications for agonists of peroxisome proliferator-activated receptors.
Gervois P; Fruchart JC; Staels B
Nat Clin Pract Endocrinol Metab; 2007 Feb; 3(2):145-56. PubMed ID: 17237841
[TBL] [Abstract][Full Text] [Related]
39. Multifaceted roles of peroxisome proliferator-activated receptors (PPARs) at the cellular and whole organism levels.
Yessoufou A; Wahli W
Swiss Med Wkly; 2010; 140():w13071. PubMed ID: 20842602
[TBL] [Abstract][Full Text] [Related]
40. Peroxisome proliferator-activated receptors in vascular biology and atherosclerosis: emerging insights for evolving paradigms.
Plutzky J
Curr Atheroscler Rep; 2000 Jul; 2(4):327-35. PubMed ID: 11122762
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
